A M&A deal was agreed and signed by Watson Pharmaceuticals, a big pharma company, with Uteron Pharma for $150 million in cash up front, and up to $155 million in potential future milestone payments.
In the wake of this m&a deal with Uteron, Watson believes that it will help in the expansion of its Global Brands pipeline of Women's Health products. This pipeline includes two potential near term global commercial opportunities in contraception and infertility, and one novel oral contraceptive, projected to launch globally in 2018.
For further deal information visit Current Agreements (subscription required)
Read: more on m&a deals in pharma, biotech, life science partnering deal news, insights and glossary
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity